Understanding the molecular characteristics of gastroesophageal adenocarcinoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to enhance knowledge about the biology of gastroesophageal adenocarcinoma and improve treatment selection. It involves two groups: one with localized cancer and another with advanced cancer. Researchers will collect tumor, blood, and microbiome samples to analyze molecular data and correlate it with clinical outcomes. The goal is to identify predictive signatures that could guide future therapies and improve patient management.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Arm 1:

* Patients with suspected or histologically confirmed localized gastroesophageal adenocarcinoma amenable to curative intent therapy with surgery as standard of care, either with or without induction chemotherapy or chemo radiotherapy.
* Age ≥18 years.
* Eastern Cooperative Group (ECOG) performance status 0-2

Arm 2

* Patients must have a histological or radiological diagnosis of advanced gastroesophageal cancer.
* Patient must have a tumour lesion that is amenable to a core needle biopsy as judged by a staff radiologist. A minimum of 3 x 18G good quality tumour cores must be safely obtainable under CT or US guidance. Biopsy to be completed before systemic therapy begins.
* Patients must have a measurable lesion by RECIST 1.1 in addition to the lesion that is going to be biopsied. See Section 13.1.3 for the evaluation of measurable disease. Patients with locally advanced gastroesophageal cancer with no metastatic disease who are not candidates for curative intent therapy as per part 1 of the protocol, are eligible for part 2 and are exempt from this criterion.
* Patients must be fit enough to safely undergo a tumour biopsy as judged by the investigator.
* Age ≥ 18 years.
* Eastern Cooperative Group (ECOG) performance status 0-2
* Life expectancy of greater than 90 days, as judged by the investigator.
* Patients plan to undergo systemic treatment with platinum-based chemotherapy (e.g. FOLFOX, CF, CX with or without Herceptin) as first line standard systemic palliative treatment, or as part of a first line clinical trial.
* Within 14 days of the proposed biopsy date, patients must have normal organ and marrow functions.

Exclusion Criteria:

Arm 1

* Patients who are planned for definitive chemoradiation without surgical resection will be excluded from this study.
* Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures.

Arm 2

* Patients with one or more contraindications to tumour biopsy according to UHN's standard biopsy procedures.
* Patients who had prior systemic treatment for advanced or metastatic gastroesophageal cancer.
* Patients who are currently on anti-cancer treatment including chemotherapy for another malignancy.
* Patients with known brain metastases are excluded from participation in this clinical study.
* Patients with advanced gastroesophageal cancer who are going to be treated with non-platinum based chemotherapy in the first line setting.
* Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
* Any condition that would, in the investigators' judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures.

Where it's running

• University Health Network
  Toronto, Ontario, Canada Recruiting

Study contacts

• Principal investigator: Elena Elimova — University Health Network, Toronto
• Study coordinator: Frances Allison
• Email: Frances.Allison@uhn.ca
• Phone: 416-340-5446

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Mesothelin-targeted CAR T-cell therapy for esophagogastric cancer

  This study is testing a new treatment that uses modified immune cells to target and attack tumors in people with advanced esophagogastric cancer.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT06623396

• Tislelizumab plus FLOT given before surgery for operable esophagus or stomach adenocarcinoma

  This trial tests whether adding the immunotherapy drug tislelizumab to FLOT chemotherapy given before surgery helps people with locally advanced, resectable esophagus or stomach adenocarcinoma shrink tumors and better tolerate treatment.

  Recruiting at 2 sites Phase 1 Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Frankfurt and 3 other locations · NCT07059299

• Combining Sintilimab with Chemotherapy for Stage III Gastric Cancer Treatment

  This study is testing if combining a new drug called Sintilimab with chemotherapy can help people with stage III gastric cancer feel better after their surgery.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT06761846

• Combining immunotherapy with chemotherapy for esophagogastric junction cancer treatment

  This study is testing if combining a new immunotherapy drug with standard chemotherapy can help people with operable esophagogastric junction cancer feel better and improve their treatment outcomes.

  Recruiting Phase 2 Ruijin Hospital · Shanghai, Shanghai Municipality · NCT06482788

• Combining anti-PD-1 therapy with thymalfasin and chemotherapy for advanced gastric cancer treatment

  This study is testing a new combination of treatments for people with advanced stomach cancer to see if it helps shrink tumors before surgery.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT06461910

• Neoadjuvant immunochemotherapy for advanced esophagogastric junction cancer

  This study is testing a new combination of immunotherapy and chemotherapy to see if it helps patients with advanced esophagogastric junction cancer before they have surgery.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT05170503

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.